Baidu
map

ESC全新重磅:房颤患者支架置入术后使用达比加群酯双联治疗大出血发生率显著低于华法林三联治疗

2017-08-28 佚名 中国医学论坛报

RE-DUAL PCI显示,与华法林三联治疗相比,达比加群酯(泰毕全)双联治疗大幅度降低出血并发症 RE-DUAL PCI中使用的两种剂量的达比加群酯均已获批用于房颤卒中预防 研究结果作为“最新突破”在2017欧洲心脏病学会年会(ESC)发布,并同时发表在《新英格兰杂志》

RE-DUAL PCI显示,与华法林三联治疗相比,达比加群酯(泰毕全)双联治疗大幅度降低出血并发症

RE-DUAL PCI中使用的两种剂量的达比加群酯均已获批用于房颤卒中预防

研究结果作为“最新突破”在2017欧洲心脏病学会年会(ESC)发布,并同时发表在《新英格兰杂志》


德国殷格翰,2017年8月27日——RE-DUAL PCI试验探索在行经皮冠状动脉介入(PCI)并行支架置入治疗的非瓣膜性房颤患者中使用达比加群酯联合一种P2Y12受体抑制剂进行双联治疗(无阿司匹林)。结果表明:达比加群酯双联治疗组大出血和临床相关非大出血事件的发生率显着低于华法林三联治疗组。达比加群酯110 mg和150 mg双联治疗组的主要安全性终点风险分别比华法林三联治疗组降低48%和28%(相对差异),总血栓栓塞事件的发生率相似。这两种达比加群酯剂量都已获得全球诸多监管机构的批准,用于非瓣膜性房颤患者的卒中预防。RE-DUAL PCI?试验结果已于今日在2017欧洲心脏病学会年会上公布,并同时发表在《新英格兰医学杂志》。

在长期口服抗凝药物以降低房颤相关卒中风险的所有房颤患者中,约20%~30%伴发冠状动脉疾病,而且可能需要采取经皮冠脉介入治疗,以改善冠脉血流及心肌灌注。对于这类患者,当前的强化抗栓标准治疗方法,即华法林和两种抗血小板药联合的三联治疗。该治疗方案与这类患者较高的大出血发生率相关。RE-DUALPCI?试验探讨了一种替代治疗策略:达比加群酯和一种非阿司匹林抗血小板药的双联治疗方案。

RE-DUAL PCI 主要研究者兼Baim临床研究所心血管代谢试验组执行总监Christopher Cannon教授说:“医生在治疗经皮冠状动脉介入伴支架置入术后的房颤患者时,必须权衡疗效及出血风险。既往我们缺少非维生素K口服抗凝剂用于此类患者的专门数据;而现在我们有了RE-DUAL PCI?试验中达比加群双联治疗方案令人鼓舞的结果,可以肯定的是此项结果必将获得正在治疗此类患者并且寻求最佳抗栓方案的医生欢迎。”

研究结果如下:

主要终点(大出血和临床相关的非大出血事件)发生率:

达比加群酯110 mg双联治疗组为15.4%,华法林三联治疗组为26.9%,相对风险降低48%;

达比加群酯150 mg双联治疗组为20.2%,华法林三联治疗组为25.7%,相对风险降低28%;

两个剂量的达比加群酯双联治疗组大出血【采用国际血栓与止血学会(ISTH)或心肌梗死溶栓的大出血定义单独分析】和总出血发生率均低于华法林三联治疗组。



关键次要终点(死亡、心肌梗死、卒中、全身性栓塞和计划外血运重建复合终点):

观察到的事件发生率相似:达比加群酯150 mg双联治疗组为13.7%,华法林三联治疗组为13.4%。


勃林格殷格翰心血管治疗领域医学副总裁Jorg Kreuzer教授说:“我们在RE-DUAL PCI试验中观测到的结果再一次有力地证实了达比加群酯对房颤患者和其治疗医生的益处。结合其他近期公布的数据来看,如导管消融RE-CIRCUIT?研究数据、‘真实世界研究’中的证据、或紧急情况下的RE-VERSE AD? 研究结果,达比加群酯的获益被反复证实,这些数据着实描绘了令人振奋的前景。”

有关RE-DUAL PCI

RE-DUAL PCI 在PCI伴支架置入的房颤患者中比较了达比加群酯+一种抗血小板的双联治疗(不含阿司匹林)和华法林+两种抗血小板药物的三联治疗。

RE-DUAL PCI 在全球41个国家的414个研究中心随机入组了2,725例行PCI伴支架置入(择期或因为急性冠状动脉综合征)的成年非瓣膜性房颤患者。

此研究的主要目的是比较110 mg或150 mg达比加群酯(每日二次)+氯吡格雷或替格瑞洛双联抗血栓疗法和华法林+氯吡格雷或替格瑞洛+阿司匹林≤100 mg(每日一次)三联抗血栓疗法。

此项研究为期30个月,旨在检验主要安全性终点的非劣效性。安全性终点定义为至首次发生ISTH定义大出血事件或具有临床意义的非大出血事件的时间。关键血栓性终点的非劣效检验为至死亡、首次血栓形成事件(心肌梗死、卒中或全身性栓塞)和计划外血运重建时间复合终点。

关于经皮冠状动脉介入(PCI)

PCI是一种介入治疗方法,利用支架扩张冠状动脉疾病患者闭塞的冠脉,目的是恢复或改善心肌灌注。欧洲大约有200万房颤患者伴发冠状动脉疾病,可能需要接受此手术。

PCI伴支架置入后的房颤患者因血栓导致的严重并发症风险增加,这些严重并发症包括卒中、全身性栓塞、心肌梗死、支架内血栓形成,甚至可能导致死亡。抗栓治疗可降低这类患者出现血栓及其后果的风险。

这些患者需要接受抗血小板治疗降低支架内血栓形成和心肌梗死的风险,同时需要接受抗凝治疗降低卒中风险。截至目前,双联抗血小板治疗与抗凝治疗联合可导致频繁的出血并发症,仍然是该领域的一个重大挑战,因而如何解决这一难题也成为该领域的研究热点。

关于达比加群酯

2013年2月达比加群酯获得中国食品药品监督管理局颁发的进口药品注册许可证,被批准用于成人非瓣膜性心房颤动患者的卒中和全身性栓塞预防,并正式在中国大陆地区上市。2017年达比加群酯被纳入中国国家医保目录。

达比加群酯在全球范围内所有获批适应症的临床使用经验已经超过790万患者年。达比加群酯的上市时间已超过8年,并已在超过一百个国家获批。

达比加群酯是一种直接凝血酶抑制剂(DTI),是首个获得广泛注册批准的新一代口服抗凝药物。直接凝血酶抑制剂通过特异性阻断凝血酶活性而发挥强效抗凝疗效,凝血酶是血栓形成过程中起核心作用的酶。与作用多个凝血因子的维生素K拮抗剂不同,达比加群可提供有效的、可预测的、可重复的抗凝效果,同时较少发生药物相互作用,无药物食物相互作用,无需进行常规凝血功能监测或强制性剂量调整。

达比加群酯是唯一一种具有已获准逆转剂的非维生素K拮抗剂类口服抗凝血药。依达赛珠单抗已在欧盟和美国获准,用于接受达比加群酯治疗、需要在急诊操作/急诊手术前或出现危及生命的或未控制的出血时迅速逆转达比加群酯抗凝效应的成人患者。依达赛珠单抗目前尚未在中国大陆获批。
原始出处:
Christopher P.Cannon,Deepak L. Bhatt,Jonas Oldgren,et al.Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.NEJM

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1766692, encodeId=ea211e6669277, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Thu Feb 22 23:10:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738236, encodeId=59671e38236fa, content=<a href='/topic/show?id=cbea19e8944' target=_blank style='color:#2F92EE;'>#三联治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19789, encryptionId=cbea19e8944, topicName=三联治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb734392571, createdName=12498768m24(暂无昵称), createdTime=Wed Jul 11 05:10:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826379, encodeId=b77d18263e982, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 16 20:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316142, encodeId=bdfa1316142e0, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549168, encodeId=bb0a154916826, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614386, encodeId=4780161438629, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238259, encodeId=0ef1238259ab, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Aug 29 07:40:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1766692, encodeId=ea211e6669277, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Thu Feb 22 23:10:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738236, encodeId=59671e38236fa, content=<a href='/topic/show?id=cbea19e8944' target=_blank style='color:#2F92EE;'>#三联治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19789, encryptionId=cbea19e8944, topicName=三联治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb734392571, createdName=12498768m24(暂无昵称), createdTime=Wed Jul 11 05:10:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826379, encodeId=b77d18263e982, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 16 20:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316142, encodeId=bdfa1316142e0, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549168, encodeId=bb0a154916826, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614386, encodeId=4780161438629, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238259, encodeId=0ef1238259ab, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Aug 29 07:40:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1766692, encodeId=ea211e6669277, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Thu Feb 22 23:10:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738236, encodeId=59671e38236fa, content=<a href='/topic/show?id=cbea19e8944' target=_blank style='color:#2F92EE;'>#三联治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19789, encryptionId=cbea19e8944, topicName=三联治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb734392571, createdName=12498768m24(暂无昵称), createdTime=Wed Jul 11 05:10:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826379, encodeId=b77d18263e982, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 16 20:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316142, encodeId=bdfa1316142e0, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549168, encodeId=bb0a154916826, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614386, encodeId=4780161438629, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238259, encodeId=0ef1238259ab, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Aug 29 07:40:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1766692, encodeId=ea211e6669277, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Thu Feb 22 23:10:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738236, encodeId=59671e38236fa, content=<a href='/topic/show?id=cbea19e8944' target=_blank style='color:#2F92EE;'>#三联治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19789, encryptionId=cbea19e8944, topicName=三联治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb734392571, createdName=12498768m24(暂无昵称), createdTime=Wed Jul 11 05:10:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826379, encodeId=b77d18263e982, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 16 20:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316142, encodeId=bdfa1316142e0, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549168, encodeId=bb0a154916826, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614386, encodeId=4780161438629, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238259, encodeId=0ef1238259ab, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Aug 29 07:40:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-30 cmsvly
  5. [GetPortalCommentsPageByObjectIdResponse(id=1766692, encodeId=ea211e6669277, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Thu Feb 22 23:10:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738236, encodeId=59671e38236fa, content=<a href='/topic/show?id=cbea19e8944' target=_blank style='color:#2F92EE;'>#三联治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19789, encryptionId=cbea19e8944, topicName=三联治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb734392571, createdName=12498768m24(暂无昵称), createdTime=Wed Jul 11 05:10:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826379, encodeId=b77d18263e982, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 16 20:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316142, encodeId=bdfa1316142e0, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549168, encodeId=bb0a154916826, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614386, encodeId=4780161438629, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238259, encodeId=0ef1238259ab, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Aug 29 07:40:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-30 xxxx1054
  6. [GetPortalCommentsPageByObjectIdResponse(id=1766692, encodeId=ea211e6669277, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Thu Feb 22 23:10:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738236, encodeId=59671e38236fa, content=<a href='/topic/show?id=cbea19e8944' target=_blank style='color:#2F92EE;'>#三联治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19789, encryptionId=cbea19e8944, topicName=三联治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb734392571, createdName=12498768m24(暂无昵称), createdTime=Wed Jul 11 05:10:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826379, encodeId=b77d18263e982, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 16 20:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316142, encodeId=bdfa1316142e0, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549168, encodeId=bb0a154916826, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614386, encodeId=4780161438629, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238259, encodeId=0ef1238259ab, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Aug 29 07:40:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1766692, encodeId=ea211e6669277, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Thu Feb 22 23:10:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738236, encodeId=59671e38236fa, content=<a href='/topic/show?id=cbea19e8944' target=_blank style='color:#2F92EE;'>#三联治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19789, encryptionId=cbea19e8944, topicName=三联治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb734392571, createdName=12498768m24(暂无昵称), createdTime=Wed Jul 11 05:10:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826379, encodeId=b77d18263e982, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 16 20:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316142, encodeId=bdfa1316142e0, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549168, encodeId=bb0a154916826, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614386, encodeId=4780161438629, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 30 10:10:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238259, encodeId=0ef1238259ab, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Aug 29 07:40:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-29 130****4638

    学习了谢谢分享

    0

相关资讯

Int J Cardiol:肥厚型心肌病伴房颤患者采用直接口服抗凝剂治疗效果如何?

由此可见,HCM伴房颤患者采用NOACs治疗显示类似的栓塞和出血发生率,相比于VKA治疗。虽然两组患者生活质量相似,采用NOAC治疗组的患者报道的治疗满意度更高。

盘点:房颤近期重要研究进展一览

近年来,房颤的全球发病率逐年增高。目前我国已经成为房颤第一大国。房颤所致的脑卒中具有高致残率、高病死率及高复发率的特点。一旦发生房颤,可使脑卒中风险增加5倍。这里梅斯医学小编整理了近期关于房颤的重要研究进展与大家一同分享。【1】房颤可增加痴呆的发生风险既往研究显示房颤患者的认知功能减退和痴呆的发生风险更高,但是房颤患者发生痴呆的相关危险因素很少有研究。近日,在国际心血管权威杂志JAHA上发表了一篇

Stroke:房颤患者进行血液透析时服用华法林的风险性

血液透析通过将体内血液引流至体外,经一个由无数根空心纤维组成的透析器中,血液与含机体浓度相似的电解质溶液(透析液)在一根根空心纤维内外,通过弥散/对流进行物质交换,清除体内的代谢废物、维持电解质和酸碱平衡;同时清除体内过多的水分,并将经过净化的血液回输的整个过程称为血液透析。本研究是在韩国人群中进行的,旨在验证房颤患者在血液透析时华法林的风险性,并将结果发表在Stroke上。

Lancet Diabetes Endo:I型糖尿病与房颤

研究发现,相对于一般人群,I型糖尿病患者房颤风险略有上升,但女性患者风险显著高于男性,血糖控制不佳以及糖尿病肾病患者的房颤风险显著上升

ESC2017重磅研究:RE-DUALPCI研究:房颤患者冠脉介入术后抗凝策略将有重大突破?

2周后,2017年欧洲心脏病学会(ESC)年会就要召开了,会上将要公布一项万众瞩目的研究:RE-DUALPCI?,该研究的目的是,对于房颤患者,在冠状动脉介入治疗(PCI)术后比较达比加群联合P2Y12抑制剂双抗,是否优于华法林联合双联抗血小板治疗?

JAHA:原发性和继发性ICD植入治疗死亡风险的比较研究

植入性除颤器(ICD)是治疗房颤的有效手段。近日,在国际心血管权威杂志JAHA上发表了一篇旨在评估ICD治疗在原发性患者和继发性患者中死亡率影响的临床研究。本研究纳入了2007年2月至2012年五月接受ICD植入的7020名患者,主要终点事件是全因死亡率。并采用多变量Cox比例风险模型来调整基线特征的差异,并分析了第一次适当ICD治疗的死亡率。最终,共有1929名(27.5%)患者接受了继发性IC

Baidu
map
Baidu
map
Baidu
map